MiNK Therapeutics (FRA:6Q40) General and Admin. Expense: €6.13 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6Q40 MiNK Therapeutics Inc FRA:6Q40
21 GF Score
Price €9.00
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics General and Admin. Expense?

MiNK Therapeutics FRA:6Q40 +4.65% 21 General and Admin. Expense is €6.13 Mil as of Mar. 2026. GuruFocus rates FRA:6Q40 with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. MiNK Therapeutics's General and Admin. Expense for the three months ended in Mar. 2026 was €1.45 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €6.13 Mil.

MiNK Therapeutics General and Admin. Expense Related Terms

MiNK Therapeutics General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics General and Admin. Expense Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
General and Admin. Expense
Get a 7-Day Free Trial 4.11 7.40 6.81 4.12 5.75

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.60 1.57 1.51 1.45
FRA:6Q40
21GF Score
MiNK Therapeutics Inc FRA:6Q40
General and Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a General and Admin. Expense of €6.13 Mil mean?
MiNK Therapeutics (FRA:6Q40) has a General and Admin. Expense of €6.13 Mil as of Mar. 2026. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' General and Admin. Expense too high?
MiNK Therapeutics' current General and Admin. Expense is €6.13 Mil. Overall, MiNK Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' General and Admin. Expense compare to BOLD and FLNA?
MiNK Therapeutics' General and Admin. Expense of €6.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current General and Admin. Expense is €6.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (FRA:6Q40) has a current General and Admin. Expense of €6.13 Mil. The current General and Admin. Expense is €6.13 Mil. MiNK Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For MiNK Therapeutics (FRA:6Q40), the current General and Admin. Expense is €6.13 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges INKT:USA
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
21GF Score

Get the complete analysis for FRA:6Q40

General and Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.00
Price